| Literature DB >> 29061864 |
Erik H Van Iterson1, Eric M Snyder2, Bruce D Johnson3.
Abstract
The predominating β-adrenergic receptor subtype expressed on human alveolar tissue is the β2AR The homozygous arginine (Arg16Arg) single-nucleotide polymorphism (SNP) at codon 16 of the β2AR gene has been associated with abnormal β2AR function accompanied by decreased resting alveolar-capillary membrane gas-transfer in certain healthy adults. Although not previously studied in the context of the β2AR gene, pulmonary gas-transfer is also influenced by alveolar volume (VA) and with it the availability of alveolar surface area, particularly during exercise. Small VA implies less alveolar surface area available for O2 transport. We tested the following hypothesis in healthy adults during exercise: compared with Gly16Gly and Arg16Gly β2AR genotypes, Arg16Arg will demonstrate reduced VA and ventilation (V̇A) relative to V̇E and oxidative metabolic demand. Age- BMI- and gender-matched groups of Arg16Arg (N = 16), Gly16Gly (N = 31), and Arg16Gly (N = 17) performed consecutive low (9-min, 40%-peak workload) and moderate (9-min, 75%-peak workload) intensity exercise. We derived VA and V̇A using "ideal" alveolar equations via arterialized gases combined with breath-by-breath ventilation and gas-exchange measurements; whereas steady-state V̇O2 was used in metabolic equations to derive exercise economy (EC = workload÷V̇O2). Variables at rest did not differ across β2AR genotype. Strongest β2AR genotype effects occurred during moderate exercise. Accordingly, while V̇E did not differ across genotype (P > 0.05), decreased in Arg16Arg versus Arg16Gly and Gly16Gly were V̇O2 (1110 ± 263, 1269 ± 221, 1300 ± 319 mL/(min·m2), respectively, both P < 0.05), V̇A (59 ± 21, 70 ± 16, 70 ± 21 L/min, respectively, both P < 0.05), and VA (1.43 ± 0.37, 1.95 ± 0.61, 1.93 ± 0.65 L, respectively, both P < 0.05). Also reduced was EC in Arg16Arg versus Arg16Gly (P < 0.05) and Gly16Gly (P > 0.05) (1.81 ± 0.23, 1.99 ± 0.30, and 1.94 ± 0.26 kcal/(L·m2), respectively). Compared with Gly16Gly and Arg16Gly genotypes, these data suggest the Arg16Arg β2AR genotype plays a role in the loss of oxidative metabolic efficiency coupled with an inadaptive VA and, hence, smaller alveolar surface area available for O2 transport during submaximal exercise in healthy adults.Entities:
Keywords: Aerobic exercise; codon 16; exercise capacity; genetic polymorphism; β2‐adrenergic receptor
Mesh:
Substances:
Year: 2017 PMID: 29061864 PMCID: PMC5661237 DOI: 10.14814/phy2.13476
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Participant characteristics
| Arg16Arg ( | Arg16Gly ( | Gly16Gly ( |
| |
|---|---|---|---|---|
| % male | 44 | 47 | 52 | 0.88 |
| Age, years | 29 ± 6 (26, 32) | 28 ± 6 (25, 31) | 29 ± 6 (27, 32) | 0.85 |
| Height, cm | 171 ± 9 (167, 176) | 176 ± 10 (171, 181) | 174 ± 10 (170, 178) | 0.41 |
| Weight, kg | 67 ± 12 (61, 73) | 76 ± 14 (67, 82) | 75 ± 13 (70, 80) | 0.14 |
| BMI, kg/m2 | 23 ± 3 (21, 24) | 24 ± 3 (22, 25) | 25 ± 4 (23, 26) | 0.21 |
| BSA, m2 | 1.79 ± 0.05 (1.68, 1.87) | 1.91 ± 0.05 (1.78, 2.01) | 1.89 ± 0.04 (1.81, 1.97) | 0.16 |
| Hemoglobin, g/dL | 13.4 ± 1.3 (12.6, 13.9) | 13.7 ± 1.1 (13.1, 14.3) | 13.7 ± 1.1 (13.2, 14.1) | 0.48 |
| Hematocrit, % | 39 ± 3 (37, 40) | 40 ± 3 (38, 41) | 40 ± 3 (38, 42) | 0.45 |
| Resting Pulmonary function | ||||
| FVC, L | 4.5 ± 0.9 (4.0, 5.0) | 5.2 ± 1.2 (4.6, 5.9) | 5.0 ± 1.1 (4.6, 5.4) | 0.16 |
| FVC, %pred. | 99 ± 13 (92, 105) | 105 ± 9 (100, 110) | 102 ± 9 (98, 105) | 0.25 |
| FEV1, L | 3.7 ± 0.7 (3.4, 4.1) | 4.1 ± 0.8 (3.7, 4.6) | 4.2 ± 0.9 (3.8, 4.5) | 0.21 |
| FEV1, %pred. | 99 ± 13 (92, 105) | 100 ± 9 (95, 105) | 103 ± 10 (99, 107) | 0.35 |
| MVV, L/min | 149 ± 27 (135, 163) | 165 ± 34 (148, 183) | 166 ± 37 (152, 180) | 0.21 |
| Peak exercise | ||||
|
| 1.2 ± 0.3 (1.1, 1.4) | 1.4 ± 0.3 (1.3, 1.6) | 1.4 ± 0.3 (1.3, 1.5) | 0.11 |
|
| 86 ± 23 (74, 98) | 98 ± 29 (82, 114) | 91 ± 22 (82, 100) | 0.41 |
| Workload, W | 185 ± 56 (156, 214) | 244 ± 64 (209, 278) | 224 ± 78 (194, 254) | 0.06 |
| HR, bpm | 189 ± 10 (184, 194) | 182 ± 9 (177, 187) | 188 ± 10 (184, 192) | 0.07 |
|
| 87 ± 31 (71, 103) | 100 ± 25 (87, 114) | 102 ± 31 (90, 113) | 0.24 |
|
| 57 ± 12 (51, 63) | 61 ± 11 (55, 67) | 61 ± 12 (57, 66) | 0.49 |
|
| 44 ± 9 (39, 48) | 41 ± 7 (37, 45) | 40 ± 7 (37, 43) | 0.31 |
|
| 1.98 ± 0.56 (1.69, 2.26) | 2.50 ± 0.66 (2.15, 2.85) | 2.56 ± 0.73 (2.29, 2.84) | 0.02 |
| RER | 1.17 ± 0.06 (1.13, 1.20) | 1.15 ± 0.05 (1.12, 0.17) | 1.15 ± 0.06 (1.13, 1.18) | 0.44 |
| RPE | 19 ± 0 (19, 19) | 19 ± 0 (19, 19) | 19 ± 0 (19, 19) | 0.07 |
| Submaximal exercise workload and energy expended | ||||
| Low, W | 70 ± 20 (60, 81) | 86 ± 22 (74, 98) | 84 ± 28 (73, 94) | |
| EE, kcal/min | 5.7 ± 1.7 (4.9, 6.6) | 6.5 ± 1.4 (5.8, 7.2) | 6.4 ± 1.6 (5.8, 7.1) | |
| Moderate, W | 139 ± 43 (116, 163) | 168 ± 45 (144, 192) | 169 ± 60 (145, 192) | |
| EE, kcal/min | 11.0 ± 3.5 (9.1, 12.8) | 13.0 ± 3.2 (11.3, 14.7) | 13.7 ± 4.7 (11.8, 15.5) | |
Data are mean ± SD and 95% lower and upper confidence limits (CL), or otherwise noted. FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec; MVV, maximum voluntary ventilation; V̇O2, pulmonary O2 uptake; HR, heart rate; V̇ E, minute ventilation; f B, breathing frequency; V T, tidal volume; RER, respiratory exchange ratio; RPE, rating of perceived exertion (Borg, 6–20 scale); EE, energy expended. Repeated measures ANOVA for group effect on submaximal exercise workload, F[91], P < 0.001; there were no pairwise differences at an alpha level of 0.05 after Tukey–Kramer post hoc correction. Test‐retest reliability of our CPET was strong [Intraclass correlation coefficient across the sample for peak workload between study 1 and 2 was 0.98 with lower and upper 95% CL: 0.95, 0.99]. P‐values in table are overall group effect from ANOVA testing.
P < 0.05, Arg16Arg versus Gly16Gly after Tukey–Kramer post hoc correction.
Figure 1Respiratory responses to low (40% peak workload) and moderate (75% peak workload) intensity exercise in healthy adults stratified by SNPs at codon 16 of ADRB2. N = 16, homozygous for amino acid arginine (Arg16Arg); N = 17, heterozygous for arginine and glycine (Arg16Gly); N = 31, homozygous for glycine (Gly16Gly). Data are interquartile range with the group means indicated by (+). (A) alveolar ventilation, V̇ A; (B) V̇A as a percentage of total minute ventilation, V̇ A/V̇ E; (C) V̇ A as a percentage of maximum voluntary ventilation V̇ A/MVV; (D) Physiological dead space to tidal volume ratio, V D/V T. *P < 0.05, Arg16Arg versus Gly16Gly; †P < 0.05, Arg16Arg versus both Arg16Gly and Gly16Gly. Significance following Tukey–Kramer post hoc correction.
Figure 2Oxygen uptake and gross metabolic demand during low (40% peak workload) and moderate (75% peak workload) intensity exercise in healthy adults stratified by SNPs at codon 16 of the ADRB2. N = 16, homozygous for amino acid arginine (Arg16Arg); N = 17, heterozygous for arginine and glycine (Arg16Gly); N = 31, homozygous for glycine (Gly16Gly). Data are interquartile range with the group means indicated by (+). A) pulmonary O2 uptake, V̇O2; (B) quotient of alveolar‐to‐arterial O2 tension gradient with V̇O2, PA‐aO 2/V̇O2; (C) exercise economy, EC; (D) net exercise economy, EC. †P < 0.05, Arg16Arg versus both Arg16Gly and Gly16Gly; ‡P < 0.05, Arg16Arg versus Arg16Gly. Significance following Tukey–Kramer post hoc correction.
Basic ventilation, alveolar air, and arterial blood responses across genotypes for the β2AR
| Arg16Arg ( | Arg16Gly ( | Gly16Gly ( | |
|---|---|---|---|
| Rest | |||
|
| 11 ± 4 (8, 13) | 10 ± 3 (8, 11) | 10 ± 4 (8, 11) |
|
| 16 ± 4 (13, 18) | 15 ± 5 (12, 17) | 14 ± 3 (13, 15) |
|
| 0.74 ± 0.44 (0.51, 0.97) | 0.75 ± 0.32 (0.55, 0.95) | 0.72 ± 0.39 (0.61, 0.84) |
|
| 0.43 ± 0.28 (0.28, 0.57) | 0.45 ± 0.30 (0.29, 0.61) | 0.42 ± 0.20 (0.34, 0.50) |
|
| 9.6 ± 6.2 (6.4, 12.8) | 8.6 ± 5.0 (6.0, 11.3) | 8.4 ± 3.2 (7.2, 9.7) |
| PAO2, mmHg | 101 ± 11 (95, 106) | 98 ± 8 (94, 103) | 98 ± 7 (95, 101) |
| PaO2, mmHg | 96 ± 14 (90, 104) | 95 ± 8 (91, 100) | 95 ± 11 (91, 99) |
| PACO2, mmHg | 33 ± 5 (31, 35) | 34 ± 3 (32, 36) | 34 ± 3 (33, 35) |
| PaCO2, mmHg | 34 ± 5 (32, 37) | 36 ± 4 (33, 38) | 36 ± 4 (34, 37) |
| CaO2, mL/dL | 18.6 ± 1.9 (17.7, 19.6) | 19.4 ± 1.7 (18.5, 20.3) | 19.4 ± 1.9 (18.7, 20.1) |
| PA‐aO2, mmHg | 6 ± 3 (4, 8) | 4 ± 3 (2, 5) | 5 ± 4 (4, 7) |
| SaO2, % | 98 ± 1 (97, 98) | 98 ± 0 (97, 98) | 98 ± 1 (97, 98) |
| Low intensity exercise | |||
|
| 35 ± 9 (30, 39) | 37 ± 7 (34 41) | 37 ± 8 (35, 40) |
|
| 26 ± 6 (23, 29) | 26 ± 5 (23, 29) | 25 ± 5 (23, 27) |
|
| 1.37 ± 0.40 (1.17, 1.58) | 1.50 ± 0.44 (1.27, 1.73) | 1.60 ± 0.49 (1.41, 1.78) |
|
| 1.04 ± 0.30 (0.88, 1.19) | 1.21 ± 0.43 (0.98, 1.44) | 1.28 ± 0.46 (1.10, 1.45) |
|
| 22.0 ± 5.3 (19.2, 24.7) | 23.6 ± 5.9 (20.4, 26.7) | 25.3 ± 6.0 (23.0, 27.5) |
| PAO2, mmHg | 104 ± 5 (101, 106) | 103 ± 3 (100, 104) | 104 ± 4 (102, 105) |
| PaO2, mmHg | 99 ± 5 (96, 101) | 99 ± 8 (94, 103) | 98 ± 6 (96, 100) |
| PACO2, mmHg | 36 ± 3 (35, 38) | 36 ± 3 (34, 37) | 36 ± 3 (35, 37) |
| PaCO2, mmHg | 37 ± 3 (35, 38) | 37 ± 3 (35, 38) | 36 ± 3 (35, 37) |
| CaO2, mL/dL | 19.2 ± 1.8 (18.2, 20.1) | 20.0 ± 1.8 (19.0, 21.0) | 20.2 ± 1.8 (19.6, 20.9) |
| PA‐aO2, mmHg | 6 ± 4 (4, 8) | 6 ± 3 (4, 8) | 7 ± 5 (5, 10) |
| SaO2, % | 98 ± 1 (97, 98) | 97 ± 0 (97, 97) | 97 ± 1 (97, 98) |
| Moderate intensity exercise | |||
|
| 75 ± 26 (61, 90) | 86 ± 19 (76, 97) | 87 ± 27 (76, 97) |
|
| 40 ± 7 (36, 44) | 38 ± 6 (34, 41) | 37 ± 8 (34, 41) |
|
| 1.85 ± 0.48 (1.59, 2.10) | 2.37 ± 0.66 (2.02, 2.72) | 2.38 ± 0.75 (2.08, 2.67) |
|
| 1.43 ± 0.37 (1.24, 1.62) | 1.95 ± 0.61 (1.62, 2.28) | 1.93 ± 0.65 (1.68, 2.19) |
|
| 32.0 ± 4.7 (29.5, 34.5) | 36.9 ± 6.4 (33.5, 40.3) | 38.0 ± 7.7 (35.0, 41.1) |
| PAO2, mmHg | 113 ± 4 (111, 115) | 112 ± 4 (110, 114) | 112 ± 4 (110, 113) |
| PaO2, mmHg | 101 ± 8 (96, 105) | 101 ± 10 (96, 106) | 98 ± 9 (95, 102) |
| PACO2, mmHg | 31 ± 4 (30, 33) | 31 ± 3 (29, 32) | 32 ± 5 (30, 34) |
| PaCO2, mmHg | 31 ± 4 (29, 33) | 31 ± 3 (28, 32) | 32 ± 3 (30, 33) |
| CaO2, mL/dL | 19.9 ± 1.9 (18.9, 20.9) | 21.0 ± 1.8 (20.0, 22.0) | 20.7 ± 1.9 (20.0, 21.4) |
| PA‐aO2, mmHg | 14 ± 5 (11, 17) | 12 ± 5 (10, 15) | 16 ± 8 (13, 19) |
| SaO2, % | 97 ± 1 (96, 97) | 97 ± 0 (96, 97) | 97 ± 1 (96, 97) |
Data are mean ± SD with lower and upper 95% confidence limits (CL) in parentheses. Low (40% peak workload) or moderate (75% peak workload) intensity exercise. F‐statistic from ANOVA for: minute ventilation (V̇ E, F[128], P < 0.0001); breathing frequency (f B, F[77], P < 0.0001); tidal volume (V T, F[54], P < 0.0001); alveolar volume (V A, F[58], P < 0.0001); VA as percentage resting forced vital capacity (V A/FVC, F[80], P < 0.0001); alveolar O2 tension (PAO2, F[54], P < 0.0001); arterial O2 tension (PaO2, F[1.3], P = 0.28); alveolar CO2 tension (PACO2, F[12], P < 0.0001); arterial CO2 tension (PaCO2, F[25], P < 0.0001); arterial O2 content (CaO2, F[48], P < 0.0001); alveolar‐to‐arterial O2 difference (PA‐aO2, F[8], P < 0.0001); and arterial saturation (SaO2, F[4.5], P < 0.0001).
P < 0.05, Arg16Arg versus Gly16Gly.
P < 0.05, Arg16Arg versus both Arg16Gly and Gly16Gly. Significance following Tukey–Kramer post hoc correction.
Figure 3Least squares univariate linear regression between total minute ventilation (V̇ E) (independent) and alveolar ventilation (V̇ A) (dependent) during low (40% peak workload) and moderate (75% peak workload) intensity exercise in healthy adults stratified by SNPs at codon 16 of the ADRB2. N = 16, homozygous for amino acid arginine (Arg16Arg); N = 17, heterozygous for arginine and glycine (Arg16Gly); N = 31, homozygous for glycine (Gly16Gly). Solid black line is model goodness of fit for the regression across the entire sample. Grey lines are isopleths representing the expected V̇ A response for a given observed V̇ E response when breathing frequency () is constrained (grey numbers within plots) for a given observed alveolar volume (V A) response. (A) Rest: Arg16Arg, Y = 0.67(X)‐1.1, P < 0.001; Arg16Gly, Y = 0.69(X)‐1.0, P < 0.001; Gly16Gly, Y = 0.63(X)‐0.5, P < 0.001. (B) 40% peak workload: Arg16Arg, Y = 0.74(X) + 0.5, P < 0.001; Arg16Gly, Y = 0.85(X)‐1.7, P < 0.001; Gly16Gly, Y = 0.85(X)‐2.5, P < 0.001. (C) 75% peak workload: Arg16Arg, Y = 0.74(X) + 2.6, P < 0.001; Arg16Gly, Y = 0.88(X)‐3.9, P < 0.001; Gly16Gly, Y = 0.82(X) + 0.3, P < 0.001.